Kezar Life Sciences, Inc.

Equities

KZR

US49372L1008

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 18/05/2024 am IST			5-day change	1st Jan Change
0.7657 ^USD	-0.30%		-0.91%	-19.18%

09/05	Kezar Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
14/03	Kezar Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Kezar Life Sciences, Inc. Announces Resignation of Christopher Kirk as President and Chief Scientific Officer

April 28, 2023 at 01:54 am IST

Kezar Life Sciences, Inc. announced that on April 21, 2023, Christopher Kirk, Ph.D. resigned from his role as President and Chief Scientific Officer of athe company. Dr. Kirk remains a member of the Board of Directors of the Company.

Latest news about Kezar Life Sciences, Inc.

Kezar Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Kezar Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03	CI
Kezar Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/03	CI
Kezar Life Sciences, Inc.(NasdaqGS:KZR) dropped from NASDAQ Biotechnology Index	15/12	CI
Wells Fargo Adjusts Price Target on Kezar Life Sciences to $2 From $4, Maintains Equal-Weight Rating	14/11	MT
Kezar Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
North American Morning Briefing : Investors Await -2-	06/23/06	DJ
JonesTrading Downgrades Kezar Life Sciences to Hold From Buy	05/23/05	MT
Kezar Life Sciences Launches Restructuring Program, Cuts Workforce, Names New CEO	04/23/04	MT
Kezar Life Sciences, Inc. Announces Executive Changes	04/23/04	CI
Kezar Life Sciences, Inc. Announces CEO Changes	04/23/04	CI
Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway	04/23/04	CI
HC Wainwright Raises Kezar Life Sciences Price Target to $20 From $18, Maintains Buy Rating	25/23/25	MT
Sector Update: Health Care Stocks Tick Lower Thursday Morning	21/23/21	MT
North American Morning Briefing : The Post-Fed Selloff Continues	21/23/21	DJ
Kezar Life Sciences Signs License Agreement With Everest Medicines to Develop, Market Zetomipzomib in Asia	21/23/21	MT
Everest Medicines Signs License Deal with Kezar for Anti-Autoimmune Disease Medication	21/23/21	MT
Stocks to Watch : FedEx, Kezar Life Sciences, Transcat	21/23/21	DJ
Everest Medicines Enters into Collaboration and License Agreement with Kear Life Sciences to Develop and Commercialize Zetomipzomib in Greater China and Other Asian Markets	21/23/21	CI
Transcript : Kezar Life Sciences, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 10:50 AM	12/23/12
North American Morning Briefing : Stock Futures -2-	14/23/14	DJ
Wells Fargo Downgrades Kezar Life Sciences to Equalweight From Overweight	11/23/11	MT
HC Wainwright Adjusts Price Target on Kezar Life Sciences to $18 From $19, Maintains Buy Rating	11/23/11	MT
Kezar Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Kezar Life Sciences, Inc.(NasdaqGS:KZR) dropped from S&P Biotechnology Select Industry Index	20/23/20	CI

Chart Kezar Life Sciences, Inc.

Duration

Period

More charts

Company Profile

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.

Sector

Biotechnology & Medical Research

Calendar

19/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Kezar Life Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.7657 USD

Average target price

11.67 USD

Spread / Average Target

+1,423.66%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KEZAR LIFE SCIENCES, INC.	-19.18%	55.74M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
BIONTECH SE	-14.15%	21.84B
ARGENX SE	-1.05%	21.96B
GENMAB A/S	-5.29%	19.21B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
BEIGENE, LTD.	-4.16%	18.08B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs